A UK biotechnology company ReGen Therapeutics, is developing a potential treatment for Alzheimer's disease based on colostrum - the first milk produced by mammals after giving birth, which offers certain immune properties. The company has acquired the rights to colostrinin, produced from colostrum, from the Polish Academy of Sciences where it has been developed for 20 years.